Filing Flows

Filing Flows › 8-K events › Senti Biosciences Holdings

Senti Biosciences Holdings: completion of an acquisition or disposition of assets

Form 8-K filed Oct 26, 2026 · items 1.01, 1.02, 2.01, 3.02

What the filing says

The information provided in the Introductory Note and Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. Celadon Partners, LLC (“Celadon”) controls Parent, Celadon Partners SPV 24 Limited, the Company’s largest stockholder, CPIF II-7 Limited, which purchased $14.0 million in aggregate pri

ScaleThe filing names $14.0M: 206× Senti Biosciences Holdings' annual revenue ($68K, four times the latest quarter).

Read the filing on SEC EDGAR →

What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 1.02: 0.0% next session across 2,368. Item 2.01: +0.1% next session across 2,671. Every item ranked →

What this kind of filing means

Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.

Item 1.02 — Termination of a material definitive agreement. Ending a material agreement can remove revenue, financing or a planned deal; the filing says who ended it and whether penalties apply.

Item 2.01 — Completion of an acquisition or disposition of assets. Completing an acquisition or a sale changes the company’s size and mix from this quarter on; the price paid and how it was financed are in the filing.

Senti Biosciences Holdings at a glance

Latest quarterQ2 2026
Revenue$17K
Operating marginn/m
IndustryBiological Products, (No Diagnostic Substances)

Senti Biosciences Holdings, Q2 2026: revenue $17K. The chart follows the revenue to costs, profit and cash.

Senti Biosciences Holdings: every quarter, Q/Q and Y/Y, holders and guidance →

Senti Biosciences Holdings’s other material 8-Ks

Other recent mergers and acquisitions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.